Navigation Links
Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
Date:5/27/2009

First clinical study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes

HAYWARD, Calif., May 27 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced it will present clinical data from a phase 1b study of ITCA 650 (DUROS(R) continuous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in New Orleans, LA (June 5-9, 2009). The study was conducted at multiple centers in the United States and evaluated a 4-week course of ITCA 650 treatment among 44 patients (n= 10-12 patients/dose arm) with type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

ITCA 650 Late-Breaker Abstract 4-LB in Category 01-C Clinical Therapeutics/ New Technology - Other Drug Delivery Systems:

A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS(R) Device Lowers Fasting and Postprandial Plasma Glucose - Luskey, K., McNally, J., Dahms, J., Logan, D., Weiner, G., Denham, D. and Alessi, T.

"We are very pleased the ADA scientific reviewers selected our study for presentation as a late-breaker," said Alice Leung, President & CEO of Intarcia Therapeutics, Inc. "Our team worked very hard to advance this program from an idea to clinical evaluation in under 18 months. In continuing this brisk pace, we expect to begin a phase 2 study of ITCA 650 in the second half of this year."

The late-breaker abstract describes the dose-ranging design of the study and preliminary results from the two lower doses of 10mcg/day and 20 mcg/day through the first two weeks of treatment. Based on the favorable tolerability of DUROS continuous delivery of exenatide on the lower doses, patients have been enrolled to two higher d
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
3. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
4. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
5. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
6. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
10. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
11. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... 2015  HealthSouth Corporation (NYSE: HLS ... post-acute healthcare services, offering both facility-based and home-based ... for the second quarter ended June 30, 2015. ... strong volume growth in both segments and an ... Grinney, President and Chief Executive Officer of HealthSouth. ...
(Date:7/29/2015)... Inc., an early stage biotech startup based on perinatal ... the Musculoskeletal Transplant Foundation of Edison NJ ... round of development of the proprietary AmnioCept™ product line ... AmnioChor,s technology allows cryopreservation of the amniotic membrane of ... those tissues. Amnion is a well-established source of multipotent ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17
... ANDS ) today announced that patient dosing has ... oral TLR7 agonist prodrug, in,patients with advanced solid tumors. ... to identify pharmacologically active doses,and preliminary antitumor activity as ... II trials., The Phase I trial is a ...
... Co., Ltd. (President:,Dr. Yuzuru Matsuda) announced that Kyowa ... U.S. subsidiary, received on February 25,2008 (local time) ... and Drug,Administration (FDA) for istradefylline (KW-6002), its investigational ... the not approvable letter FDA expressed concern if ...
... at North Carolina State University have demonstrated that ... chemically different so-called Janus particles will ... field is applied to liquid surrounding the particles. ... the Feb. 8, 2008, edition of Physical Review ...
Cached Biology Technology:Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002) 2'2-faced' particles act like tiny submarines 2
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Latin America Biomedical Sensors Market Report 2015-2020 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... CITY , Jan. 24, 2013 /PRNewswire-iReach/ -- Amiigo, ... has developed a new device for gesture recognition and ... that uses accelerometers and machine learning algorithms to automatically ... device knows if users are using the elliptical trainer ...
... than geologists previously thought, according to new research results. ... put very small samples of peridotite, rock derived from Earth,s ... found that the rock can and does liquify, at least ... deep as 250 kilometers down in the mantle beneath the ...
... leading experts will meet today in Brussels, Belgium, to ... research and the key findings of FLAVIOLA an ... health benefits and potential applications. Members of the FLAVIOLA ... researchers to review the outcomes of FLAVIOLA,s research and ...
Cached Biology News:Amiigo Unveils Fitness Tracker That Knows What Exercise You're Performing 2Magma in Earth's mantle forms deeper than once thought 2Magma in Earth's mantle forms deeper than once thought 3Recent breakthroughs in cocoa flavanol research discussed by European research consortium and expert panel 2